

EFORT Implant & Patient Safety Initative Brussels, 2020-01-21

Matthias Fink, M.D. Bassil Akra, PhD



Mehr Sicherheit. Mehr Wert.

Choose certainty.

Add value.





Disclaimer

Official Journal L 117 of the European Union



Legislation



Volume 60


5 May 2017

This presentation is based on information available as of today and prepared to my best knowledge as subject matter expert.

This presentation presents my personal understanding of the medical device requirements in Europe and is not reflecting the view of TÜV SÜD PS.



Important changes & improvements*



^{*} Source: http://ec.europa.eu/growth/tools-databases/newsroom



Data Quality for Orthopedic Implants

- Historical data often medium to low quality
- Limitations of published literature (study design, endpoints, bias, data gaps,...)
- Limitations of Post Market Clinical Follow-Up (PMCF) Studies
 - extrapolation to Real World Data
- **□** Registries
 - ✓ Validation? IMDRF Guidance?
 - ✓ Data on safety and performance?
 - ✓ Ad-hoc Reports




Data Quality for Orthopedic Implants



- High quality clinical studies, covering all device variants, all indications, all patient (sub-)
 populations, full device lifetime
- High quality studies with some gaps that can be closed with other evidence
- High quality data from Registries and/or other high volume Real World Data
- Studies with potential methodological flaws but where data can still be quantified and acceptability justified
- Common Specifications
- Reliable data on equivalent devices
- State-of-the-Art evaluation (no safety and performance concerns for similar devices)
- Sales, complain and vigilance data (high volume)
- Case reports
- Usability testing (e.g. cadaver lab), animal studies
- Bench testing, compliance with standards




Major elements of PMS



Article 120.3: However, the requirements of this Regulation relating to post-market surveillance, market surveillance, vigilance, registration of economic operators and of devices shall apply in place of the corresponding requirements in those Directives.



Clinical Aspects - Processes, Plans (P), Reports (R), Summary (S)



Post-Market Surveillance



Examples of ACTIVE Methods

Planned Customer Surveys

Prospective and retrospective
Post-market clinical investigations or studies

Company-supported Investigator-Sponsored Studies (ISS)

Extended clinical investigations

Company registry based on the output of the risk management file and the CER

Planned Analysis of Regional or National Device Registries - Hospital Databases, Registries



Examples of REACTIVE Methods

Customer Complaints /Incidents

User Feedback

Investigator Initiated Studies (IIS)

Literature Review

Published Data from Regional or National Device Registries

Expert Opinion



Real World Data

- Patient Registries (e.g. National Arthroplasty Registries)
 - National
 - Regional
 - Local, institutional
 - Manufacturers
- Reimbursement and discharge data
 - Data held by Health Insurances
 - Internal quality monitoring at public health institutions
- Data generated by active medical devices
- Telemedicine related to medical and diagnostic devices
 - Apps
 - Monitoring of diagnostic measures by physicians





Common understanding documents "Guidance Documents"

Current Status

Various Task Forces of the EU Commission are working on:

- Guidance on sampling of medical devices Published
- Explanatory note on MDR codes Published
- Guidance and templates for PSURs
- Guidance and template for SSCPs Published
- Guidance on classification of Software as a Medical Device Published
- Guidance and templates for PMCFs
- Guidance for sufficient clinical data
- Guidance for equivalence approach Gap Document to MEDDEV 2.7.1 Rev. 4
- Common specifications, Clinical Evaluation Guidance for Software, etc.
- Implementing act for reprocessing single use medical devices



